In this clinical trial, we will assess pressure ulcer healing rates in critically ill patients supplemented with IV Alanyl-Glutamine in comparison with critically ill patients not supplemented with alanyl-glutamine.
This clinical trial will include 200 Egyptian Critically ill patients with bed sores equal or more than grade II selected from ward or ICU at Air Force specialized Hospital. They will be classified into 2 groups: * Group I: 100 critically ill patients will be enrolled on high protein diet and receiving IV alanyl Glutamine with dose 0.3 gm/kg/ day which equal 1.5 ml/kg/day of alanyl-glutamine until discharge from ICU, death (with duration of 2 weeks administration). * Group II: 100 critically ill patients will be enrolled on high protein diet either enteral or parenteral but not receiving any glutamine supplementations.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
200
Amino acid solution for parenteral nutrition containing dipeptide alanyl-glutamine
Air Force Specialized Hospital
Cairo, New Cairo, Egypt
RECRUITINGPercentage change in pressure ulcer length
Final ulcer length/original ulcer length x 100
Time frame: 2 weeks
Percentage change in pressure ulcer depth
Final ulcer depth/original ulcer depth x 100
Time frame: 2 weeks
Percentage change in pressure ulcer area
Final ulcer area/original ulcer area x 100
Time frame: 2 weeks
Percentage change in proportion of viable wound tissue
Final proportion of viable wound tissue /original proportion of viable wound tissue x 100
Time frame: 2 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.